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Summary Uptake of L-methyl-"C-methionine ("C-methionine) in breast cancer metastases was studied
with positron emission tomography (PET). Eight patients with soft tissue metastases were studied twice: before
! the onset of chemotherapy (4), hormonal therapy (3) or radiotherapy (1) and 3-14 weeks later. The
radioactivity concentration of the low molecular weight fraction of venous plasma samples separated by fast
gel filtration was used as input function. The input corrected uptake rate of "C-methionine (K,) in breast
cancer metastases before the treatment ranged between 0.035 and 0.186 1 min' and the standardised uptake
value (SUV) between 2.0 and 11.4. The uptake of "C-methionine into the metastases decreased when clinical
objective stability or regression of the metastases was later obtained and increased in cases where progressive
disease was seen during treatment. We conclude that metabolic changes in the amino acid metabolism detected
by PET precede the clinical response, and may be of clinical value in predicting the treatment response.
In oncology the evaluation of treatment response to cancer
therapy is a fundamental issue and is usually aided by
radiological or nuclear imaging. Positron emission
tomography (PET) has opened a totally new approach in
evaluating metabolical changes in cancer tissue caused by
chemotherapy or radiotherapy in vivo. Using a glucose
analogue '8F-2-fluoro-2-deoxy-D-glucose (FDG) and PET
imaging may be a valuable method in predicting treatment
response in head and neck cancer (Minn et al., 1988), breast
cancer (Minn & Soini, 1989) and lung cancer (Abe et al.,
1990). Active metabolism may be visualised by radiotracers
such as FDG or L-methyl-"C-methionine ("C-methionine)
which take part in altered turnover of glucose or amino acids
in cancer tissue (Kubota et al., 1985; Wahl et al., 1991).
Methionine is necessary in cancer cells for increased pro-
tein and polyamine synthesis and in transmethylation reac-
tions. This essential amino acid has a central role in the
altered metabolism of malignant cells (Hoffman, 1990). The
amino acid metabolism of cancer tissue can be studied in vivo
by measuring uptake of "C-methionine by PET. The uptake
has been reported to decrease rapidly as a response to radia-
tion therapy in an experimental tumour model (Kubota et
al., 1989) and to bromocriptine treatment in pituitary
adenomas (Bergstrom et al., 1987).
We studied the uptake of "C-methionine in breast cancer
metastases to find out whether the change in the uptake
during cancer therapy could predict the clinical response to
treatment.
Materials and methods
Patients
Eight patients with breast cancer who had progressive meta-
static disease were consented to undergo a PET study. The
study was approved by the Ethical Committee of Turku
University Central Hospital. Only patients with soft tissue
metastases were accepted to the study: five patients with
supraclavicular or axillary lymph node metastases, two with
pleural and one with pulmonary metastases. All patients
studied were included in the analysis. PET scanning was
performed twice with each patient: before the onset of the
new therapy and 3-14 weeks later (median 7 weeks). Patient
1 (Table I) received palliative radiation therapy (megavoltage
therapy 40 Gy). Three patients were treated with hormone
therapy: Patient 2 received high dose toremifene (anti-
estrogen) treatment, patient 3 tamoxifen and patient 8
medroxyprogesterone acetate. Four patients received chemo-
therapy: Patients 4 and 5 received combination of cyclo-
phosphamilde, metotrexate and fluorouracil and patients 6
and 7 received weekly low dose epidoxorubicin. Patients 3, 4
and 5 were studied under their first therapeutic intention,
patients 6 and 2 under their second therapeutic intention,
patients 1 and 7 under their fourth therapeutic intention and
patient 2 under her ninth therapeutic intention (Table I).
The size of the metastases was recorded at the time of the
first PET study, the time of the second PET study and finally
3-6 months after the beginning of the therapy, at which time
the clinical response was evaluated according to the criteria
of WHO (Miller et al., 1981). The maximal diameter of the
palpable lymph node metastases ranged from 2 to 5 cm
except one axillary lymph node with a diameter of 7 cm
(Table I, patient 1). The maximal diameter of the thickest
part of the two pleural metastatic processes was 3 cm on
chest X-ray (Table I, patients 2 and 7) and that of the
pulmonary hilus metastasis was 3 cm on chest X-ray (Table
I, patient 3). The size of the metastases did not change
significantly during the interval between the two PET studies
except in the case of the 7 cm axillary lymph node metastasis,
which shrunk to 5 cm in diameter. Duration of the response
and survival of the patients was evaluated after 2 years from
the PET study.
PET imaging
The patients had a light protein-poor breakfast 3 to 4 h
before PET scanning. An ECAT Scanner type 931/08-12 was
used for PET imaging. The device acquires 15 contiguous
slices simultaneously with a slice thickness of 6.7 mm; the
transaxial full width half maximum is 6.1 mm in the center of
the field of view (Spinks et al., 1988).
"C-methionine was synthesised at Turku University Radio-
chemistry Laboratory as described elsewhere (Langstr6m et
al., 1987). The purity of "C-methionine was higher than
92,5%, except in two studies, where it was 82.0% (study I of
patient 6) and 89,0% (study II of patient 8). The remaining
radioactivity was mainly in the form of "C-methionine sul-
phoxide as discussed elsewhere (Nagren, 1992). Prior to emis-
sion scan, a transmission scan was carried out using a retrac-
table ring source containing 68Ge. This entailed a 15 min scan
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Table I Patient characteristics
Size of Number of
Age Weight Tumour the tumour Therapeutic therapies
Pat (yrs) (kg) location (cm) modality before PET
1. 80 87 Axillary lymphnode 7 RT 3
2. 59 78 Pleura 3 H 8
3. 63 77 Pulmonary hilus 3 H 0
4. 63 78 Supraclavicularlymph node 2 CT 0
5. 51 71 Supraclavicularlymph node 3 CT 0
6. 56 72 Supraclavicularlymph node 3 CT 1
7. 73 77 Pleura 3 CT 3
8. 77 60 Axillary lymph node 5 H I
RT = radiotherapy, H = hormonal treatment, CT = chemotherapy.
of the clavicular region and a 20-25 min scan for the trunk.
"C-methionine (160-320 MBq) was injected into an upper
extremity vein. After the injection, the dynamic emission
scanning was carried out for 60min the frame times being
4 x 30s, 3 x 60s, 5 x 180s, 4 x 300s and 2 x 60s.
Blood sampling
Frequent venous blood samples were taken during the emis-
sion scanning from a cubital vein contralateral to the injec-
tion site. A total of 17 blood samples were taken, ten of
which during the first 3 min after the injection. To ease the
blood sampling the arm was first heated with a pad. The
radioactivity concentration of the plasma samples was deter-
mined. The low molecular weight fraction ofplasma samples,
which consists mainly of "C-methionine, taken at 10, 20, 40
and 60 min after the injection was separated by fast gel
filtration (Sephadex PD-10 columns, Pharmacia Fine Chemi-
cals, Sweden) and the radioactivity concentration was deter-
mined for curve fitting.
ROI analysis
One or more regions of interest (ROIs) in two to three planes
were drawn on the hot spots in the tumour. The size of the
ROIs was restricted to the highest accumulation area and
was always smaller than the total tumour area. The ROI
with the maximum average counts in the frame representing
the time between 35 and 40 min of the dynamic study was
selected to represent the 11C-methionine uptake in the tumour
in the analysis of the standardised uptake value (SUV). The
respective time activity curve was used in the kinetical
analysis.
Kinetical analysis
A graphical approach according to Patlak was used to
analyse the irreversible "C-methionine uptake in the tumour
tissue (Patlak et al., 1983). In this method normalised plasma
time values are plotted on the horizontal and the tissue
activity values divided by plasma activity values on the verti-
cal axis:
T
x(T) = {cp (t) dt/Ct (T)
0
y(T) = Cp (T)/Ct (T)
where Cp (t) is the plasma radioactivity concentration of the
tracer at time t, T is the frame mean time after injection and
Ct (T) is the tracer concentration of tumour tissue at time T.
When y(T) is plotted against x(T) a straight line with a slope
of Ki (influx constant) is obtained. The slope represents the
accumulation rate of the tracer from the plasma to the
irreversible tissue compartment. The influx constant was cal-
culated from the regression line obtained from seven to ten
data points in the straight line of the Patlak plot representing
the evaluation time between 11 min to 40 min after the injec-
tion. The last frames between 40-60 min post injection were
omitted because the tissue time activity curve gradually
decreased after 40 min in one study (Leskinen-Kallio et al.,
1992a).
Standardised uptake values (SUV)
Radioactivity concentration in the tumour ROI per dose
corrected by body weight, the standardised uptake value
(SUV), was calculated for each patient according to the
following formula (Oldendorf, 1974; Woodard et al., 1975;
Strauss & Conti, 1991):
SUV = ROI radioactivity concentration [Bq/ml]
Injected dose [BqJ / patient weight [g]
The ROIs representing the frametimes between 35 and
40 min were selected for SUV analysis. The uptake of "1C-
methionine was assessed without knowledge on the clinical
response.
Results
The soft tissue metastases of all the eight breast cancer
patients were clearly visualised with "C-methionine (Figure
1). The uptake of "C-methionine was rapid and achieved a
plateau in 10 to 15 min (Figure 2). When the radioactivity
concentration of the low molecular weight fraction of plasma
was used as an input function in the graphical analysis
according to Patlak, a straight line was obtained in the plot
at 11 min after injection. The line was straight in all studies
from 25 to 40 min, and the influx constant was calculated of
seven to ten data points of this period (Figure 3).
A partial remission was seen in three cases (Table IT). The
Ki decreased in two of these cases (a decrease of 48% and of
15%) and remained the same in the remaining case (a de-
crease of 2%). Of the five cases with progressive disease, the
Ki increased in four (an increase of 12%, 15%, 19% and
68%) and decreased slightly in one metastasis (a decrease of
5%) (Table II). The SUVs of all metastases that responded
to the therapy decreased, increased in three and remained the
same in two of the five metastases that progressed during
treatment (Table III). The greatest difference between the two
uptake values was observed in a responding pulmonary meta-
stasis that was studied after a 13 week interval (patient 3).
The uptake rate (Ki) before the start of the new thera-
peutic modality ranged from 0.035 to 0.186 min-' and the
SUV from 2.5 to 11.4, respectively. The Ki measured during
the therapy ranged between 0.030 and 0.143 min-' and the
SUV between 2.0 and 7.8. The highest uptake of "C-methi-
onine was measured in a pulmonary metastasis, where the Ki
was 0.186 min-' and the SUV 11.4 (patient 3). This patient
experienced a long lasting, strong partial response to tamoxi-
fen treatment, and she is surviving after 2 years of the PET
studies. No correlation was obtained between the number of
previous therapeutic intentions, or rapidity of progression of
the disease, and the uptake rate of "C-methionine.
There was a good correlation between the Ki and SUV in
this series (r = 0.86, P <0.0001, n = 16) (Figure 4).11C-METHIONINE AND PET IN BREAST CANCER 789
Figure I A pulmonary metastasis of breast cancer in the right hilar region imaged by "C-methionine and PET (Patient 3).
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Figure 2 A typical time activity curve for "C-methionine activity in a breast cancer metastasis during the PET study (Patient 3).
Table II The input corrected uptake values Ki (I) before the onset
of the treatment and during the treatment Ki (II)
Time interval
K, (I) Ki (HI) Clinical between PET
Patient min-' min-' response studies (weeks)
1. 0,065 0,063 PR 7
2. 0,048 0,080 PD 14
3. 0,186 0,096 PR 13
4. 0,063 0,072 PD 6
5. 0,120 0,143 PD 7
6. 0,058 0,066 PD 7
7. 0,088 0,083 PD 3
8. 0,035 0,030 PR 7
P = partial response, PD = progressive disease.
Table III The standardised uptake value before the onset of the
treatment SUV(I) and during the treatment SUV (II)
Time interval
Clinical between PET
Patient SUV(I) SUV(II) response studies (weeks)
1. 5,6 5,0 PR 7
2. 3,8 6,2 PD 14
3. 11,4 7,4 PR 13
4. 3,8 4,1 PD 6
5. 4,6 7,8 PD 7
6. 5,2 5,9 PD 7
7. 4,4 4,3 PD 3
8. 2,5 2,0 PR 7
P = partial response, PD = progressive disease.
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Figure 3 Graphical analysis for a "C-methionine PET study according to Patlak (Patient 3). The slope of the regression line
represents the influx constant K, (see text).
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Figure 4 Correlation between the input corrected uptake rate of "C-methionine K, and the standardised uptake value SUV.
Discussion
In our study, all breast cancer soft tissue metastases had a
clear uptake of "C-methionine. In three of the five progres-
sing metastases the uptake values increased and remained the
same in two, and decreased in all the three regressing meta-
stases.
In one of the cases (patient 7, Table II) the interval
between the two PET studies was short, only three weeks,
and there was no change in the Ki or in the SUV. At least
this reflects good reproducibility of the PET method.
Clinical response to anticancer therapy in breast cancer is
usually not evaluable until in 2 to 3 months. There are
several therapeutic modalities, and there is an increasing need
for predictive methods for treatment response. A rapid and
reliable method for evaluation of long-term treatment re-
sponse would be of value e.g. in chemotherapy, which may
cause severe side effects. Estrogen and progesterone receptor
content and expression of epidermal growth factor receptors
are predictors of endocrine therapy response (Nicholson,
1989), but they may fail in a significant proportion of cases.
Assessing tumour amino acid metabolism by "C-methionine
and PET may provide a more effective predictive method for
evaluating individual treatment response.
"C-methionine has formerly been reported to be an effec-
tive tracer to image gliomas, lung cancer, lymphomas and
breast cancer with PET (Derlon et al., 1989; Fujiwara et al.,
1989; Leskinen-Kallio et al., 1991a; Leskinen-Kallio et al.,
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1991b). The uptake of '"C-methionine may be associated with
the malignancy grade of these tumours (Leskinen-Kallio et
al., 1991 a and 1992b).
The graphical analysis method according to Patlak (Patlak
et al., 1983) has been applied to "C-methionine PET tumour
studies by Bergstrom et al. (1986), Hatazawa et al. (1989)
and ourselves (Leskinen-Kallio et al., 1991a). As an input
function we used the radioactivity concentration of the low
molecular weight fraction of plasma, which consists mainly
of "C-methionine and not its metabolites (Lundqvist et al.,
1985). A straight line was obtained in the plot during 11 to
40min of the study. This represents the irreversible uptake
"C-methionine from plasma to the cancer tissue. This
method requires 40 min emission scanning time, several
blood samples, and the separation of the low molecular
weight fraction of the plasma by fast gel filtration or measur-
ing the "C-methionine concentration by high pressure liquid
cromatography. In this material, there was an excellent cor-
relation between the SUVs and Kis. For SUV analysis, only 5
to 10 min emission scanning time is needed 20 to 30 min after
injection. SUV analysis seems to be an adequate method for
clinical PET studies with "C-methionine in breast cancer
(Leskinen-Kallio et al., 1992a).
In measuring the accumulation of "C-methionine in the
tumour several factors may affect the ultimate count
detected. The differences in the tumour blood flow (Abe et
al., 1990), physiological circumstances such as the body
temperature, the location of the tumour in the field and the
complex metabolism of methionine (Hoffman, 1984) should
be beared in mind when interpreting the results of PET
studies. The error marginal in PET studies is approximately
5% (Spinks et al., 1988). Minimising these errors and pro-
viding the quality and reproducibility of PET studies needs
strict standardisation of the study protocol and regular nor-
malisation and calibration of the scanner.
Breast cancer metastases even with the diameter of 2 cm
can be imaged with "C-methionine and PET. An increase in
the uptake of "C-methionine 6 to 7 weeks after the beginning
of anticancer therapy may predict poor response. Further
studies with a larger patient material are needed. Different
scanning intervals need to be tested to get more information
about changes in amino acid metabolism in breast cancer
metastases, and the value of PET in evaluating the treatment
response.
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